Market Research Logo

Global Bacterial Vaginosis Drugs Market 2017-2021

About Bacterial Vaginosis Drugs

BV is a vaginal disease caused due to complex alteration of flora present in the vagina. Antibacterial drugs are used for the treatment of BV, some of the most common drugs used for the treatment of the disease include Metronidazole, Clindamycin, and Tinidazole. The drugs are used in both oral and topical forms. Two types of bacteria are found in the genital parts of the women, termed as good bacteria and bad bacteria. The good bacteria present in the vagina are lactobacilli, which prevents the growth of bad bacteria.

Technavio’s analysts forecast the global bacterial vaginosis drugs market to grow at a CAGR of 2.16% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global bacterial vaginosis drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Bacterial Vaginosis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bayer
  • Pfizer
  • Sanofi
  • Starpharma Holdings
Other prominent vendors
  • Allergan
  • AstraZeneca
  • Cardinal Health
  • Mylan
  • Novartis
  • Sun Pharmaceutical Industries
  • Symbiomix Therapeutics
  • Teva Pharmaceutical Industries
Market driver
  • Unmet demand in BV treatment market
  • For a full, detailed list, view our report
Market challenge
  • Development of resistance against antibiotics
  • For a full, detailed list, view our report
Market trend
  • Growing awareness about controlled use of antibiotics
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Bacterial Vaginosis Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global bacterial vaginosis drugs market: Bayer, Pfizer, Sanofi, and Starpharma Holdings.

Other Prominent Vendors in the market are: Allergan, AstraZeneca, Cardinal Health, Mylan, Novartis, Sun Pharmaceutical Industries, Symbiomix Therapeutics, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is growing awareness about controlled use of antibiotics. Antibiotic resistance is one of the major problems being faced by the medical world today. It is a condition wherein an microorganism changes itself and remains no longer sensitive to that particular antibiotic. Thus, the antibiotic will no longer be capable of killing or inhibiting the growth of bacteria.”

According to the report, one driver in the market is unmet demand in BV treatment market. Unmet demand in the treatment of BV has created great opportunity for the market players. There is huge unmet need in the treatment of BV, especially the recurrent form of the disease. BV is the most common vaginal infection in the women of child bearing age group. Despite being highly prevalent in nature, little has been done in the field. When left untreated, it may lead to severe infections, especially in the case of pregnant women such as preterm births.

Further, the report states that one challenge in the market is development of resistance against antibiotics. The development of multidrug-resistant microbes is one of the major threats to the human health. The microbe changes itself to protect against the antimicrobial agent used and thereby develops resistance to the drug. This develops largely due to the irrational use of drugs. Incorrect prescription of the drugs by physicians or incorrect dosing or course taken by patients leads to the development of resistant drugs. This occurs because of the increased accumulation of drugs in the body. The commonly used antibiotic drugs thus become ineffective against microbes, leading to aggravation of disease in the body.

Companies Mentioned

Bayer, Pfizer, Sanofi, Starpharma Holdings, Allergan, AstraZeneca, Cardinal Health, Mylan, Novartis, Sun Pharmaceutical Industries, Symbiomix Therapeutics, and Teva Pharmaceutical Industries.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Risk factors for BV
      • Table Symptoms, diagnosis, and treatment of BV
  • Market landscape
    • Market overview
      • Table Global BV drugs market snapshot
    • Market size and forecast
      • Table Global BV drugs market 2016-2021 ($ millions)
      • Table Opportunity analysis of global BV drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline analysis
    • Table Key pipeline molecules by vendors
    • Table Global BV drugs market: Key trials
  • Market segmentation by ROA
    • Table Global BV drugs market by ROA 2016
    • Table Global BV drugs market by ROA 2016 and 2021
    • Table Basis for the choice of routes
    • Oral
      • Table Advantages and disadvantages of oral route of drug administration
      • Table Global BV oral drugs market 2016-2021 ($ millions)
    • Topical
      • Table Advantages and disadvantages of topical drugs
      • Table Global BV topical drugs market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Segmentation of global BV drugs market by geography 2016 and 2021
    • Table Global BV drugs market revenue by geography 2016-2021 ($ millions)
    • BV drugs market in Americas
      • Table Market scenario in Americas
      • Table BV drugs market in Americas 2016-2021 ($ millions)
    • BV drugs market in EMEA
      • Table Market scenario in EMEA
      • Table BV drugs market in EMEA 2016-2021 ($ millions)
      • Table Prevalence rate of BV in Europe
    • BV drugs market in APAC
      • Table Market scenario in APAC
      • Table BV drugs market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Complications associated with BV
      • Table Pregnancy complications due to BV
      • Table Symptoms of PID
      • Table Sociocultural factors preventing females from quality health services
      • Table Women health programs
    • Market challenges
      • Table Resistance for clindamycin
  • Market trends
    • Growing awareness about controlled use of antibiotics
      • Table Major causes of antibiotic resistance
    • Rising popularity of topical drugs and other treatment options such as probiotic drugs
  • Vendor landscape
    • Table Competitive structure analysis of global BV drugs market 2016
  • Key vendor analysis
    • Bayer
      • Table Bayer: Key highlights
      • Table Bayer: Strength assessment
      • Table Bayer: Strategy assessment
      • Table Bayer: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Sanofi
      • Table Key highlights
      • Table Sanofi: Strength assessment
      • Table Sanofi: Strategy assessment
      • Table Sanofi: Opportunity assessment
    • Starpharma Holdings
      • Table Starpharma: Key highlights
      • Table Starpharma: Strength assessment
      • Table Starpharma: Strategy assessment
      • Table Starpharma: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report